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significant cause of hospital admission. In order to 
stratify patients according to the risk of the compli­
cations, such as rebleeding or death, and to predict the 
need of clinical intervention, several risk scores have 
been proposed and their use consistently recommended 
by international guidelines. The use of risk scoring 
systems in early assessment of patients suffering from 
UGIB may be useful to distinguish high­risks patients, 
who may need clinical intervention and hospitalization, 
from low risk patients with a lower chance of developing 
complications, in which management as outpatients 
can be considered. Although several scores have 
been published and validated for predicting different 
outcomes, the most frequently cited ones are the Rockall 
score and the Glasgow Blatchford score (GBS). While 
Rockall score, which incorporates clinical and endoscopic 
variables, has been validated to predict mortality, 
the GBS, which is based on clinical and laboratorial 
parameters, has been studied to predict the need of 
clinical intervention. Despite the advantages previously 
reported, their use in clinical decisions is still limited. This 
review describes the different risk scores used in the 
UGIB setting, highlights the most important research, 
explains why and when their use may be helpful, reflects 
on the problems that remain unresolved and guides 
future research with practical impact.
Key words: Upper gastrointestinal bleeding; Risk scores; 
Risk assessment; Rockall score; Glasgow blatchford 
score
© The Author(s) 2016. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: Upper gastrointestinal bleeding (UGIB) remains 
a significant cause of hospital admission. In order to 
stratify patients according to the risk of complications, 
such as rebleeding or death, and to predict the need 
of clinical intervention, several risk scores have been 
proposed and their use consistently recommended 
by international guidelines. This review describes the 
different risk scores used in the UGIB setting, highlights 
the most important research, explains why and when 
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Abstract
Upper gastrointestinal bleeding (UGIB) remains a 
REVIEW
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their use may be helpful, reflects on the problems that 
remain unresolved and guides future research with 
practical impact.
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INTRODUCTION
Acute upper gastrointestinal bleeding (UGIB) remains a 
common cause of visits to the Emergency Department, 
with an estimated incidence of about 100 per 100000 
hospitalizations[1], and being associated to significant 
morbidity, 30 d mortality and health-care costs[2,3].
Many risk factors are known to influence the out-
come in UGIB setting. Age, comorbidities, presence of 
shock, endoscopic diagnosis, haemoglobin values at the 
time, ulcers’ size, stigmata of recent haemorrhage and 
need for a blood transfusion have all been described as 
significant risk factors for rebleeding and death[4-8].
Patients suffering from UGIB are generally admitted 
for observation with or without upper endoscopy. How-
ever, emergency endoscopy is not continuously available 
in many hospitals. An United Kingdom audit of 6750 
patients suffering from UGIB has revealed that only 52% 
of the hospitals had an out-of-hours endoscopy service 
and only 50% patients received endoscopy within 24 
h[9].
In order to stratify the risk of complications, reb-
leeding, need of clinical intervention or death, several 
clinical scores are in use. Although recommended in the 
prevailing guidelines[10,11] they are erratically applied in 
the clinical practice. To encourage the use of a risk score 
in the context of UGIB, it should be easy to calculate, 
contain easy access variables, have high accuracy in 
predicting relevant outcomes and distinguish low-risk 
from high-risk patients.
The purpose of this paper is to describe the different 
risk scores already in use, explain why and when they 
may be useful, reflect on their limitations in clinical pra­
ctice and direct future investigations. Since the majority 
of the literature is limited to non-variceal UGIB (NVUGIB), 
this review article will focus on such condition.
UPPER GI BLEEDING RISK SCORES - 
WHO? 
From the different UGIB risk scores described, three 
main groups can be established: The scores only require 
endoscopic parameters, those that incorporate clinical 
and endoscopic parameters and those based solely on 
clinical parameters.
Score with endoscopic variables only
Forrest classification is based on endoscopic findings of 
an ulcer and is still useful to stratify patients into high- 
and low-risk categories in terms of rebleeding[12]. 
The Forrest classification divides ulcers in six diffe­
rent categories, depending on the endoscopic findings. 
High risk lesions include those characterized by spurting 
haemorrhages (Forrest Ⅰa), oozing haemorrhages 
(Forrest Ⅰb), nonbleeding visible vessels (Forrest Ⅱa), 
adherent clots (Forrest Ⅱb). Low risk lesions include 
haematin on the ulcer base (Forrest Ⅱc), and clean 
ulcer base (Forrest Ⅲ).
Forrest Ⅰa, Ⅰb and Ⅱa lesions require endoscopic 
treatment. For the ulcers with adherent clots (Forrest 
Ⅱb) clot removal should be attempted by vigorous 
irrigation and should be treated according to the under-
lying lesion[13,14].
Clinical and endoscopic scores 
The most cited score incorporating clinical and endo-
scopic elements is the Rockall score. However, other 
scores such as the Baylor Bleeding Score (BBS), the 
Cedars-Sinai Medical Centre Predictive Index (CSMCPI), 
and more recently the progetto nazionale emorragia 
digestiva (PNED) score have also been reported.
The Rockall score, which ranges from 0 to 11, was 
developed in 1996 to predict mortality due to UGIB[15]. 
This score incorporates five variables: Age, haemo-
dynamic status, patient’s comorbidities, endoscopic 
diagnosis and presence of major stigmata of recent 
haemorrhage (Table 1). Patients’ stigmata of recent 
haemorrhage (blood in upper gastrointestinal tract, 
adherent clot, visible or spurting vessel) are recognised 
risk factors for rebleeding, surgery and death and are 
indications for endoscopic therapy[16-18].
The BBS was originally developed for predicting 
rebleeding in patients with non-variceal haemorrhage[19]. 
This scoring system, which ranges from 0 to 24, is 
divided into three parts: (1) a pre-endoscopy score 
based on age and number and severity of concurrent 
diseases; (2) an endoscopic score based on site 
and stigmata of bleeding; and (3) a post-endoscopy 
score, which includes both the pre-endoscopy and the 
endoscopy score (Table 2).
The CSMCPI was developed as a guideline for 
determining the appropriate length of stay for patients 
admitted suffering from UGIB. Developed in 1996, by 
Hay et al[20], CSMCPI is based on four variables previ-
ously identified as independent predictors of outcome 
in patients suffering from UGIB : Endoscopic findings, 
symptoms at the time, haemodynamic instability, and 
number of comorbidities. The CSMCPI ranges from 0 to 
11 (Table 3).
An Italian score of 10, the PNED score[21], was 
developed and validated to predict 30 d mortality after 
non-variceal bleeding. The PNED score is based on ten 
variables, (8 clinical and 2 laboratorial), and ranges 
from 0 to 24 (Table 4). 
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Scores with clinical variables only
Several studies have tried to develop clinical scoring 
systems to stratify the patients’ risks based on the 
data immediately available at the time of the visit to 
the Emergency Department. These risk scores can be 
used to help physicians decide on the need for hospital 
admission, inpatient monitoring level and time for endo-
scopic evaluation.
Clinical risk scores may be useful to identify high-
risk patients requiring immediate intervention and low-
risk patients that can be safely discharged[11]. The main 
clinical scores reported in the literature are the clinical 
Rockall score and the Glasgow-Blatchford Score (GBS). 
Other scores such as the AIMS65 and the T-score were 
only recently described.
The clinical Rockall score is calculated without the 
endoscopic findings[15,22] (Table 1), and only includes 3 
clinical variables: The patient’s age, the haemodynamic 
status, and the occurrence of a comorbid disease. A 
maximum score of 7 is possible.
The GBS incorporates 8 clinical or laboratorial 
variables (heart rate, haemoglobin value, blood urea 
nitrogen, systolic blood pressure, melena occurrence, 
syncope, hepatic disease, or heart failure) (Table 5). 
The GBS ranges from 0 to 23, with higher scores in-
dicating higher likelihood of a need for an endoscopic 
intervention.
Saltzman et al[23] developed an acronymic risk score 
named AIMS65 which incorporates albumin level < 3.0 
g/dL (A), international normalized ratio (INR) > 1.5 (I), 
altered mental status (M), systolic blood pressure ≤ 90 
mmHg (S), and age > 65 years (65) (Table 6).
An Italian study developed the T-score which 
included 4 clinical parameters commonly assessed in the 
UGIB setting: (1) general conditions (poor, intermediate, 
good); (2) pulse (< 90 beats/min, 90-110 beats/min, 
> 110 beats/min); (3) systolic blood pressure (< 90 
mmHg, 90-110 mmHg, > 110 mmHg); and (4) haemo-
globin level (≤ 8 g/dL, 9-10 g/dL, > 10 g/dL)[24] (Table 7).
Although some other non-endoscopic scores have 
been developed, they still present some limitations 
which preclude their use in the clinical practice. For 
example, the Cambridge score[25], described by Cameron 
and colleagues, incorporates 14 clinical and laboratorial 
variables, but has not been externally validated. An 
American score based on artificial neural networks (ANN) 
has been assessed, not only as a means to predict 
endoscopic findings, but also for the need for endoscopic 
treatment in patients suffering from UGIB[26,27]. However, 
it requires the inclusion of 27 of the patients’ variables 
and a specialized computer software for analysis.
THE IMPORTANCE OF OUTCOMES 
When should we use a risk score?
Despite methodological and demographic differences, 
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Score 0 1 2 3
Variable 
Age < 60 yr 60-79 yr ≥ 80 yr
Shock No shock, systolic BP ≥ 100, pulse 
< 100
Tachycardia, systolic BP ≥ 100, 
pulse ≥ 100
Hypotension, systolic BP < 100
Comorbidity No major comorbidity Cardiac failure, ischaemic heart 
disease, any major comorbidity
Renal failure, liver failure, 
disseminated malignancy
Diagnosis Mallory-Weiss tear, no lesion 
identified and no SRH
All other diagnoses Malignancy of UGI tract
Major SRH None or dark spot only Blood in UGI tract, adherent clot, 
visible or spurting vessel
Table 1  Rockall score
Admission score: Sum of age, shock and comorbidity; full score: Sum of age, shock, comorbidity, diagnosis and major SRH; BP: Blood pressure (measured 
in mmHg); UGI: Upper gastrointestinal; SRH: Stigmata of recent haemorrhage.
Pre-endoscopy score 1 2 3 4 5
Age (yr) 30-49 50-59 60-69 ≥ 70
No. of illnesses 1-2 3-4 > 5
Severity of illnesses Chronic1 Acute2
Endoscopy Score
Site of bleeding Posterior wall bulb
Stigmata of bleeding Clot Visible vessel Active bleeding
Table 2  Baylor bleeding score
Pre-endoscopy score: Sum of the scores for age and the number and severity of concurrent illnesses; Endoscopy 
score: Sum of the scores for site and stigmata of haemorrhage; Post-endoscopy score: Sum of the pre-endoscopy 
and endoscopy score; 1Chronic: Presence of a concurrent chronic life-threatening illness; 2Acute: Presence of a 
concurrent acute life-threatening illness.
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was closely correlated with the probability of death, but 
not so close to the chance of rebleeding[30-32,34,35]. This 
observation may be partly explained by the fact that the 
Rockall score was originally developed for the prediction 
of mortality rather than for the prediction of rebleeding 
and also because not all patients received endoscopic 
therapy[15].
The clinical Rockall score, without endoscopy, can 
be used to improve the quality of patients’ care by 
identifying those patients less likely to require intensive 
health care services and selecting them for endoscopic 
evaluation as outpatients, allowing substantial resource 
savings. 
Tham et al[22] reported that patients classified as low 
risk, i.e., clinical Rockall score of 0, can be managed in 
the outpatient setting because these patients had no 
adverse outcomes and did not require transfusion.
Phang et al[36] demonstrated that clinical Rockall may 
be helpful to determine the appropriate environment 
into which UGIB patients should be admitted. In this 
study 60.5% of the patients with a clinical Rockall score 
of < 4 (low risk) had a mortality rate of 3.2%, meaning 
that they could have been managed in a general ward. 
On the other hand, from the 39.5% of patients with a 
clinical Rockall score of ≥ 4 (high risk), the mortality 
had a rate of 22.4%, indicating that those patients 
should be admitted to an intensive care unit. However, 
Gralnek et al[37] found that the complete rockall Score 
identified more low­risk patients than the clinical Rockall 
score.
Regarding peptic ulcer disease, BBS was initially 
proposed to predict rebleeding after endoscopic therapy, 
but was rarely used in the clinical practice. The original 
BBS study revealed that the cut-off of ≥ 11 had a 
sensitivity of 100% and a specificity of 79% for the 
prediction of rebleeding[19]. The same authors who 
the outcomes evaluated in the different studies are rela-
tively similar. However, when attempting to implement 
different scoring systems in clinical practice it is 
important to know the primary outcome variable that 
was measured in each developed study. A summary of 
the main outcomes of each score is listed in Table 8.
There is evidence that most of the mortality in 
patients suffering from NVUGIB is not directly related to 
bleeding[3]. So, adding clinical variables to a risk score 
may increase its ability to predict a specific outcome.
The Rockall score should be used as a tool for 
identifying patients with low risk of rebleeding and 
death according to the clinical and endoscopic risk 
factors. Patients with Rockall scores of less than or 
equal to 2 should be considered for management in 
the community. This score was prospectively derived 
from 4185 cases of UGIB over a 4 mo period in 1993 
and was afterwards validated by the same investigators 
on the following year in 1625 cases from the same 
hospitals[15]. A higher Rockall score indicates a higher 
risk of a poor outcome. In a prospective validation of 
this score, Rockall et al[28] showed that the patients 
with a score of 2 or less (29.4% of the cohort) had a 
rebleeding rate of 4.3% and a mortality rate of 0.1%, 
suggesting that such patients could have been safely 
managed in the outpatient setting.
The Rockall score has been prospectively and exte-
rnally validated in different populations[29-32]. Church and 
Palmer from Edinburgh proposed that the Rockall score 
could be used to predict rebleeding and death by doing 
a retrospective analysis of cases of peptic ulceration 
enrolled into two trials of endoscopic haemostasis. The 
authors showed a correlation between the Rockall score 
and mortality or rebleeding. Patients with scores of 8 or 
greater had a significantly poorer outcome[33].
Several studies have shown that the Rockall score 
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Score EGD findings1 Time2 Haemodynamics Comorbidities
0 Ulcer without SHR, non-bleeding MW tear > 48 h Stable ≤ 1
Erosive disease, normal EGD
1 Ulcer with flat spot or clot, erosive disease with SHR, angiodysplasia < 48 h Intermediate 2
2 Ulcer with non- bleeding visible vessel or SHR In hospital Unstable 3
3 ≥ 4
4 Persistent haemorrhage, varices
UGI cancer
Table 3  Cedars-sinai medical centre predictive index
1Score for endoscopic findings was reduced by 1 point if effective endoscopic therapy was applied (not applicable to varices or cancer); 2Time from onset 
of symptoms to hospitalization; SHR: Stigmata of recent haemorrhage; MW: Mallory-Weiss tear; EGD: Esophagogastroduodenoscopy; UGI: Upper 
gastrointestinal.
Score 1 2 3 4
Variables ASA 3 Hb level ≤ 7 g/dL Rebleeding Failure of endoscopic
Time to Age ≥ 80 ASA 4 treatment
admission < 8 h Renal failure Neoplasia
Liver cirrhosis
Table 4  Progetto nazionale emorragia digestiva score
ASA: American Society of Anaesthesiology; GI: Gastrointestinal.
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created this score had validated it prospectively in a 
cohort of 47 patients with bleeding peptic ulcer who had 
undergone endoscopic therapy[38]. Twenty-six patients 
were categorized as high-risk and 19 as low-risk. The 
rebleeding rate for high-risk patients was 31% and 0% 
for low-risk patients.
The CSMCPI may help to select low-risk patients 
suitable for early discharge[20,39]. In the original study 
of Hay et al[20] patients with a CSMCPI of 3 were 
considered suitable for discharge within 24 h. Seventy 
percent of UGIB patients (349 of 500) were considered 
as low-risk according to this cut-off. Complications 
occurred in 2 patients (0.6%) classified as low-risk. 
The routine use of the CSMCPI was associated with a 
reduced time of admission in 79% of all low-risk cases 
with a potential reduction of 2.1 bed-days per patient. 
An italian study compared the three main endos-
copy-based scores (CSMCPI, BBS and Rockall) and 
found out that the full Rockall score was superior in 
predicting mortality and rebleeding, particularly in low 
risk patients. In this study all scores were better at 
predicting mortality than rebleeding[29].
Marmo et al[21] developed the PNED score to predict 
30 d mortality in patients suffering from acute NVUGB 
and validated it in a large cohort of patients. The PNED 
score is simple, reliable and accurate in identifying high-
risk patients (score > 4 points) most likely to benefit 
from high levels of care and prevent death[21]. In a 
previous study the PNED score was significantly more 
accurate than the Rockall score in predicting death in 
non-variceal bleeders. This score introduces the failure 
to perform endoscopic haemostasis as a variable. As a 
matter of fact, in a former study by the same authors, 
the impossibility to perform endoscopic therapy was the 
strongest predictor of a negative outcome, being thus 
associated with an 11-fold risk of death[40].
The GBS should be used to predict the need for 
treatment (blood transfusion, endoscopic therapy or 
surgical intervention). This clinical score was developed 
from a prospective cohort involving 1748 patients 
admitted for UGIH in 19th centres in Scotland[41]. The 
greatest feature of the GBS is its ability to identify 
low-risk patients (GBS = 0) who do not need to be 
admitted into a hospital. With a high sensitivity and 
a high negative predictive value, the GBS indicates 
that almost all patients with a score equal to 0 can 
be safely discharged. In return, its positive predictive 
value remains low due to the low specificity (32%), 
significantly overestimating the risk of poor outcomes. A 
GBS of 0 was validated in the United Kingdom to safely 
discharge patients from Emergency Departments with 
suspected UGIB: Eighty-four patients with a GBS equal 
to 0 were managed as outpatients without adverse 
events during the follow-up[42]. In another United 
Kingdom study, 142 low-risk patients were managed 
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Table 5  Glasgow blatchford score
Variable Score
Albumin < 3 g/dL 1
International normalized ratio > 1.5 1
Systolic blood pressure < 90 mmHg 1
Altered mental status 1
Age > 65 yr 1
Table 6  AIMS65 Score
Score 1 2 3
Variable
General conditions Poor Intermediate Good
Pulse (beats/min) > 110 90-110 < 90
Systolic blood pressure (mmHg) < 90 90-110   > 110
Haemoglobin levels (g/dL) ≤ 8 9-10 > 10
Table 7  T-score
Scores Primary outcome Original studies
Endoscopy based score
Forrest classification Rebleeding [12]
BBS Rebleeding [19]
CSMCPI Mean length of stay [20]
Rockall Mortality [15] 
PNED Mortality [21]
Clinical scores
Clinical rockall Mortality [15]
GBS Need intervention [41] 
AIMS65 Mean length of stay/mortality [23]
T-score Time to endoscopy [24,65]
Table 8  Outcomes
BBS: Baylor bleeding score; CSMCPI: Cedars-sinai medical centre 
predictive index; PNED: Progetto nazionale emorragia digestiva; GBS: 
Glasgow blatchford score.
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1Known history or clinical and laboratory evidence, of chronic or acute 
liver disease; 2Known history or clinical and echocardiographic evidence, 
of cardiac failure.
without admission, and none of them required endoscopic 
intervention, blood transfusion or surgery. In this cohort 
of patients the 28 d mortality rate was 0[43].
The GBS has been shown to be as good as the 
Rockall score in predicting the need for any intervention, 
namely the need for therapeutic endoscopy[41,42,44-47]. 
The GBS has also been shown to be superior to the 
clinical Rockall score in identifying patients with sus-
pected UGIB who have a low likelihood of an adverse 
clinical outcome (blood transfusion, endoscopic therapy, 
interventional radiology, surgery or 30 d mortality) and 
can be considered for early discharge[48].
A multicentre study by Stanley et al[47] found that 
the GBS was equivalent to both the full and clinical 
Rockall scores in predicting death. It was however 
superior to the clinical Rockall score, and similar to the 
full Rockall score in predicting the need for endoscopic 
therapy or surgical intervention and superior to both in 
predicting the need for blood transfusion. This late fin­
ding is similar in both scores, because the GBS includes 
the measurement of haemoglobin levels on admission.
A study by Ahn et al[49] including patients with cancer 
who visited the Emergency Department, reported a 
greater accuracy of the GBS when compared to the 
Rockall score in predicting intervention in those patients.
Clinical variables such as liver disease, cardiovascular 
disease, presence of syncope, altered mental status and 
melena are susceptible to a subjective interpretation in 
GBS. Thus, a modified GBS could be used to eliminate 
subjective variables. A multicentre North American 
study reported that a modified GBS (without urea or 
syncope variables) was superior to the clinical Rockall 
score in predicting high risk of endoscopic stigmata 
in bleeding or rebleeding[50]. Another North American 
study has only incorporated the four quantitative 
variables, eliminating the subjective variables such as 
history of syncope, presence of melena, liver disease, 
cardiovascular disease, as well as altered mental status. 
The reported conclusion is that the modified GBS 
performed as well as the full GBS while outperforming 
both clinical and endoscopic Rockall Scores for prediction 
of clinical outcomes[51].
Some studies have suggested that the rate of 
identified low­risk patients could be increased by using 
a higher GBS cut-off value[45,52-57] or by incorporating 
age as a variable[52,58]. Stephens et al[52] showed that 
there was a relationship between age and significant 
endoscopic findings in patients categorized as low-
risk by GBS. In this study, patients with a GBS of ≤ 
2, for each additional year of age, had the chance of 
a significant endoscopic finding increased by 8%. The 
authors concluded that using GBS ≤ 2 and age of less 
than 70 years to define low­risk patients allows 10.5% 
of patients suffering from UGIB to be safely managed 
in the community. Over a 5-year period of managing 
such patients without hospital admission, McLaughlin 
et al[43] showed that any of them required endoscopic 
intervention, blood transfusion or surgery, and that 
the 28 d mortality was nil. A recent multicentre Danish 
study reported that a GBS cut-off value of ≤ 1 and 
an age modified low-risk version can be safely and 
effectively used to reduce unnecessary admissions for 
suspected UGIB[55].
AIMS65 can potentially be used to predict in-hospital 
mortality, length of stay, and cost in patients with acute 
UGIB[23]. When more than two components of AIMS65 
are present, the mortality risk is considered to be high. 
Hyett et al[59] has reported the superiority of the 
AIMS65 score when compared to the GBS in predicting 
inpatient mortality, but inferiority in predicting the need 
for blood transfusion. In a north American retrospective 
study, the AIMS65 showed no ability to predict the need 
for blood transfusion[60]. In a retrospective Japanese 
study, the AIMS65, but not the GBS, was considered 
an independent prognostic factor for poor overall sur-
vival[61]. On the other hand, in a recent study by Jung 
et al[62], the AIMS65 was insufficient in predicting 
outcomes in peptic ulcer bleeding.
In a recent Turkish study, the GBS was found 
to have superior sensitivity when compared to the 
AIMS65 score in identifying patients who were not 
likely to require interventions, including emergency 
endoscopy[63]. Such finding can be linked to the lower 
number of variables considered in this score. This score 
may not be able to detect low-risk patients with UGIB, 
but further studies are required.
Masaoka et al[64] recently proposed an algorithm to 
assess the mortality risk, which consisted in applying 
the AIMS65 score after detecting low-risk patients with 
GBS ≤ 2.
The T-score can be used to triage patients who are 
likely to have high-risk endoscopic stigmata and there-
fore need intervention[24]. It has the ability to predict 
high-risk endoscopic stigmata, rebleeding and mortality 
with an accuracy similar to the GBS[65]. According to 
Tammaro and collaborators, a T-score of ≤ 6 was able 
to predict the presence of high risk endoscopic stigmata 
and the need for an early endoscopy with a specificity 
of 96% and a positive predictive value of 74.5%[65].
Das et al[26] showed that ANN was superior to the 
admission Rockall score and similar to the full Rockall 
score to predict the need for endoscopic intervention, 
but its applicability in clinical practice is complex and 
time consuming.
Therapeutic decisions - why or why not should we use a 
risk score?
The consensus opinion recommends the early use 
of risk stratification scores in patients suffering from 
UGIB[10,11,13]. Many of these differ in the outcomes they 
were suggested for (risk of mortality, rebleeding and 
need for therapeutic intervention). However, in the era 
of increased outpatient management of UGIB, predicting 
the need for therapeutic intervention may be as useful 
as predicting rebleeding and death. Stratification risk 
systems could reduce the resources and costs without 
adversely influencing the patients’ outcomes[66].
The greatest interest of clinical scores lies in their 
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ability to identify patients at low risk of complications 
who are suitable for early discharge without endoscopy. 
There is considerable evidence from several geographical 
regions (both in the United Kingdom and around the 
world)[41,42,44,46,48,56] that the GBS is an excellent risk 
assessment tool and accurately identifies patients with 
a low risk of requiring intervention or death. However, 
the best GBS cut-off for these situations is not clearly 
defined. Moreover, using a cut­off of 0 to predict low risk 
for adverse events has a practical limitation, since most 
of the patients who visit the Emergency Department 
with UGIB will score at least 1 point[41,42,46,65,67]. Possible 
explanations for the reported cut-off variation are 
differences in the demographics characteristics, aetiology 
of UGIB, routine use of proton pump inhibitors before 
endoscopy and adherence to guidelines regarding the 
need for endoscopic therapy.
Although with high sensitivity to identify patients at 
high risk for developing the need for blood transfusion, 
endoscopic therapy, or surgical intervention, the GBS 
has a low specificity[44,45,48,56,68,69]. 
Advanced age is a risk factor for death[70] and low-
risk patients in general are younger than high-risk 
patients with UGIB. Despite not including age and being 
developed for predicting clinical intervention after UGIB 
detection, the GBS has proven to be equivalent to the 
Rockall score in predicting death[47]. Nevertheless, the 
ability of the GBS to identify low-risk patients may be 
enhanced by incorporating age as a variable[52,58].
Although there is greater consensus that certain 
endoscopic findings are associated with a high risk for 
adverse outcomes (e.g., active bleeding or non-bleeding 
visible vessel), and other findings indicate a low risk for 
such outcomes (e.g., clean-base ulcer, Mallory-Weiss 
tear), some controversy remains in what concerns 
the need of endoscopy as a component for early risk 
stratification at the initial patients’ triage[71].
Almost all patients in the low risk group of the Rockall 
score had no stigmata of recent haemorrhage[29,35] and 
in clinical practice decisions regarding patient length of 
stay, admission place (intensive care unit versus regular 
ward) and therapeutic decisions are usually made on 
the basis of endoscopic appearance rather than the 
Rockall score[13]. The Forrest classification has shown a 
higher specificity and positive predictive value for the 
prediction of rebleeding and death when compared to 
other four scoring systems that were evaluated (the 
Rockall, the CSMCPI, the GBS and the BBS scores)[34].
The responsibility for initial patient assessment lies 
on the Emergency Department staff who invariably are 
general physicians or surgeons and may be uncomfor-
table about discharging patients without an endoscopy. 
Thus, although the GBS has shown a great ability to 
detect patients with low risk of complications in the 
Emergency Department setting, an endoscopy continues 
to support the patient management. On the other hand, 
by adopting a policy of urgent endoscopies in all patients 
with acute UGIB, several patients will undergo an 
unnecessary urgent procedure.
Another important key question in the management 
of patients with UGIB is the timing of the endoscopy, 
even though the overall consensus suggests that it 
should be performed within 24 h from admission[10]. 
Earlier endoscopy was not associated with a reduction in 
mortality or need for surgery. However, it was associated 
with an increased efficiency of care, a potential improve­
ment in the control of haemorrhage in high-risk patients, 
and a reduction in the length of stay. All these factors 
support the routine use of early endoscopies, unless 
specific contraindications occur[72,73].
The Rockall Score is unable to address this question, 
since it requires endoscopic findings. A retrospective 
study by Lim et al[74] revealed that performing an endos-
copy within 13 h for high-risk patients with a GBS of > 
12 is associated with a reduced mortality. The timing 
of urgent endoscopy following an episode of UGIB may 
be also differentiated according to the simplified clinical 
T-score of ≤ 6[65].
The need for a therapeutic endoscopy may also be 
a subjective decision[75] and a score that would equally 
help endoscopists in the decision to perform an urgent 
intervention is still warranted. Ideally, simple clinical 
scores could facilitate the identification of high-risk 
patients who could benefit from an early endoscopy with 
therapeutic intervention. Farooq et al[76] reported that 
the use of clinical Rockall and GBS was less accurate 
than a clinical triage decision in predicting the need for 
endoscopic therapy. In the study by Attar et al[67], the 
GBS showed an equivalent sensitivity when compared 
to endoscopists (both 98%) in the detection of urgent 
upper endoscopy necessity. However, both GBS and 
endoscopists showed a very poor specificity, being 
unable to detect non urgent patients to endoscopy.
In a recent multicentre study, although clinical know-
ledge of the endoscopists (described as “gut feeling”) 
was an independent predictor for an adverse outcome, 
it had a lower sensitivity and a worst predictive power 
compared to prediction scores[77].
The reasons for not using clinical scores may be that 
they are difficult to calculate and time consuming and do 
not add much information to the physician’s knowledge. 
Furthermore, no clinicians will feel comfortable in mana-
ging an elderly patient as an outpatient even if he has 
a GBS of 0. When there is clinical concern on avoiding 
admission in elderly patients, the use of an age modified 
GBS should be considered[55]. 
In real life, patients may also take antiplatelet and 
anticoagulant medications that may further increase the 
rebleeding rate and mortality, an issue not addressed in 
most reported studies. However, the AIMS65 includes 
the INR as a risk factor and an INR > 1.5 has been 
shown to be independently associated with in-hospital 
mortality in acute NVUGIB in a recent multicentre United 
Kingdom national audit[78].
The variables of AIMS65, with the exception of blood 
pressure, are different from those in the GBS. Albumin 
level and age may also contribute to the superiority of 
this score for the prediction of mortality[59]. Furthermore, 
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it has advantages over the existing risk scores, including 
the fact of being easy to remember and lacking the 
subjectivity in its calculation. 
All scores seem to have lower performance in high-
risk patients. Most clinical scores have poor specificity, 
possibly leading to unjustified upper endoscopies in the 
emergency context. However, the sensitivity of these 
scores may be likely more important than specificity, 
since they may help in physician’s decisions, ensuring 
that any patient who may have a poor prognosis is 
discharged.
Extending the definition of low­risk patient may lead 
to outpatient management of patients who may actually 
need clinical intervention. Indeed, the cut-off value 
for considering patients to be at low or high risk may 
depend on local healthcare assistance and outpatient 
support and therefore needs to be carefully assessed in 
different populations.
Personalized medicine can help in stratification of 
patients according to biomarkers and guide optimal 
treatment and prevention. The molecular pathological 
epidemiology (MPE) is a recently established interdisci-
plinary and transdisciplinary field, which emerged from 
the complex relationship between etiological factors, 
molecular alterations, and disease evolution[79,80]. MPE 
may stratify UGIB into different subtypes according to 
the pathogenic mechanisms, enabling a more efficient 
and individualized approach.
To date, most of MPE research is applied to can-
cer[81,82], but this approach may also be important to 
UGIB and further investigation is needed to evaluate its 
contribution.
CONCLUSION
We believe that the value of risk scores in predicting 
the outcomes in acute UGIB has been proven far 
beyond any scepticism. Routine use of scoring systems 
by unspecialized medical staff could save lives, alert 
to the severity of a patient’s condition and lead to an 
immediate referral. Furthermore, it could be an auxiliary 
tool for endoscopists that are often asked to perform 
an urgent endoscopy and have to decide whether the 
procedure should be done immediately or delayed 
up to 24 h. Endoscopic based scores can determine 
intensive care strategies, endoscopic therapy and 
length of hospitalization. As a means to predict low risk 
patients amenable to an early discharge and outpatient 
management, the Rockall and GBS are the two most 
commonly used and recommended risk stratification 
systems[13]. 
T-score, recently described, can potentially be useful 
to predict high-risk endoscopic stigmata and the need 
of early intervention[65]. We recommend the use of non-
endoscopic scores as the pre-endoscopic Rockall score 
or the GBS, as a decision tools for patients with acute 
UGIB. The scores may be useful when endoscopy are 
not available in the emergency department. A patient 
with Rockall score or the GBS equal to 0 can be safely 
discharged.
Moreover, we also advocate early endoscopy (within 
12 to 24 h of admission) and early discharge of patients 
with low risk lesions or low post-endoscopic risk scores 
(e.g., post-endoscopic Rockall score ≤ 2). 
Theoretically, the perfect score would be applicable 
in the two different stages of the patient’s assessment, 
pre- and post-endoscopy, with excellent accuracy for 
the main outcomes in the context of UGIB: Rebleeding, 
death, and need of clinical intervention. However, 
since both scores have reached sufficient levels of 
efficiency that enable their safe employment in clinical 
practice, and until further research proves this premise, 
endoscopists should continue to rely on their “gut 
feeling” and on all the endoscopic findings as the key 
factors to guide their therapeutic decisions in patients 
with UGIB. 
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